James H.A. Clubb - Concepedia

Author

James H.A. Clubb

Also Known As

J. CLUBB, J. Clubb, J. H. A. Clubb, James Clubb, James H A Clubb, James H. A. Clubb, James H.A. Clubb, James HA Clubb, James Hugo Armstrong Clubb

Publications

359

Citations

H-Index

Concepts

All Affiliations

University of Helsinki Helsinki University Hospital Biocenter Finland Finnish Food Authority Institute for Molecular Medicine Finland

About

James H.A. Clubb is an author at University of Helsinki specializing in medicine, immunotherapy, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	96
2	Immunology	4	4	85
3	Cell Biology	2	2	29
4	Engineering	1	1	11
5	Biomedical Engineering	1	1	11

James H.A. Clubb

Publications

315

Citations

H-Index

Page 1

	Year	Citations
Comparison of Clinically Relevant Oncolytic Virus Platforms for Enhancing T Cell Therapy of Solid Tumors Víctor Cervera-Carrascón, Dafne C.A. Quixabeira, Riikka Havunen, Molecular Therapy — Oncolytics	2020	44
Adenovirus Encoding Tumor Necrosis Factor Alpha and Interleukin 2 Induces a Tertiary Lymphoid Structure Signature in Immune Checkpoint Inhibitor Refractory Head and Neck Cancer James H.A. Clubb, Tatiana V. Kudling, Camilla Heiniö, Frontiers in Immunology	2022	44
Systemic Delivery of Oncolytic Adenovirus to Tumors Using Tumor-Infiltrating Lymphocytes as Carriers João M. Santos, Camilla Heiniö, Dafne C.A. Quixabeira, Cells ImmunologyPathologyTil TherapyImmunotherapyTumor Biology	2021	34
Local delivery of interleukin 7 with an oncolytic adenovirus activates tumor-infiltrating lymphocytes and causes tumor regression Tatiana V. Kudling, James H.A. Clubb, Dafne C.A. Quixabeira, OncoImmunology	2022	34
Safety, Efficacy, and Biological Data of T-Cell–Enabling Oncolytic Adenovirus TILT-123 in Advanced Solid Cancers from the TUNIMO Monotherapy Phase I Trial Santeri A. Pakola, Katriina Peltola, James H.A. Clubb, Clinical Cancer Research	2024	24
Effective intravenous delivery of adenovirus armed with TNFα and IL-2 improves anti-PD-1 checkpoint blockade in non-small cell lung cancer Tatiana V. Kudling, James H.A. Clubb, Santeri A. Pakola, OncoImmunology Effective Intravenous DeliveryImmunologyImmunoeditingImmunotherapeuticsAnti-pd-1 Checkpoint Blockade	2023	22
Local therapy with an engineered oncolytic adenovirus enables antitumor response in non-injected melanoma tumors in mice treated with aPD-1 Dafne C.A. Quixabeira, Víctor Cervera-Carrascón, João M. Santos, OncoImmunology Apd-1 Monoclonal AntibodyImmunologyImmunoeditingImmunotherapeuticsApd-1 Therapy	2022	18
The oncolytic adenovirus TILT-123 with pembrolizumab in platinum resistant or refractory ovarian cancer: the phase 1a PROTA trial Matthew S. Block, James H.A. Clubb, Johanna Mäenpää, Nature Communications	2025	15
Overcoming effector T cell exhaustion in ovarian cancer ascites with a novel adenovirus encoding for a MUC1 bispecific antibody engager and IL-2 cytokine Saru Basnet, Mirte Van der Heijden, Dafne C.A. Quixabeira, Molecular Therapy	2024	14
Single intravenous administration of oncolytic adenovirus TILT-123 results in systemic tumor transduction and immune response in patients with advanced solid tumors Elise Jirovec, Dafne C.A. Quixabeira, James H.A. Clubb, Journal of Experimental & Clinical Cancer Research	2024	12

Page 1